NEWS RELEASE: WHO issues warning on falsified medicines used for diabetes treatment and weight loss

20 June, 2024

World Health Organization

NEWS RELEASE: WHO issues warning on falsified medicines used for diabetes treatment and weight loss

Visit site-

WHO issues warning on falsified medicines used for diabetes treatment andweight loss

20 June2024 -- The World Health Organization (WHO) issued a medical product alerton falsified semaglutides, the type of medicines that are used for treatment oftype 2 diabetes and obesity in some countries.

The alert addresses 3falsified batches of product of semaglutide class of medicines (of specificbrand Ozempic), which have been detected in Brazil in October 2023, the UnitedKingdom of Great Britain and Northern Ireland in October 2023, and the UnitedStates of America in December 2023. WHO Global Surveillance and MonitoringSystem (GSMS) has been observing increased reports on falsified semaglutideproducts in all geographical regions since 2022. This is the first officialnotice issued by WHO after confirmation of some of the reports.

“WHOadvises healthcare professionals, regulatory authorities and the public beaware of these falsified batches of medicines,” said Dr Yukiko Nakatani, WHOAssistant Director-General for Essential Medicines and Health Products. “Wecall on stakeholders to stop any usage of suspicious medicines and report torelevant authorities”.

Prof Joseph Ana

Lead Senior Fellow/ medicalconsultant.

Center for Clinical Governance Research &

Patient Safety (ACCGR&PS) @ HRI GLOBAL

P: +234 (0) 8063600642


8 Amaku Street, State Housing, Calabar,Nigeria.

HIFA Profile: Joseph Ana is the Lead Senior Fellow/Medical Consultant at the Centre for Clinical Governance Research and Patient Safety (CCGR&PS) with Headquarters in Calabar, Nigeria, established by HRI Global (former HRIWA). He is the Country Coordinator for PACK Nigeria (Practical Approach to Care Kit) which is specifically designed to improve clinical competence (improving accuracy of diagnosis and treatment) in primary health care. He is also a Member of the World Health Organisation’s Technical Advisory Group on Integrated Care in primary, emergency, operative, and critical care (TAG-IC2). As the Cross River State Commissioner for Health (2004-2008), Joseph Ana led the introduction of the evidence based, homegrown quality tool, the 12-Pillar Clinical Governance Programme (12-PCGP) in Nigeria, which also suitable for lower-, low-, and middle income countries (LLMIC) with similar weak health sector and system. To ensure sustainability of 12-PCGP, the ‘Department of Clinical Governance, Servicom & e-health’ was established in Cross River State Ministry of Health in 2007. His main interest is in ‘Whole health sector and system strengthening in LLMICs’. He has written six books on the 12-Pillar Clinical Governance Programme, including the TOOLS manual for its Implementation, currently in its 2nd Edition. He served as Chairman of the Nigerian Medical Association’s Standing Committee on Clinical Governance (2012-2022), and he won the Association’s ‘Award of Excellence’ on three consecutive occasions for the innovation of 12-PCGP in Nigeria. He served as Chairman, Quality & Performance subcommittee of the Technical Working Group for the implementation of the Nigeria Health Act 2014. He was Member, National Tertiary Health Institutions Standards Committee (NTISC) of the Federal Ministry of Health, 2017-2022. He is the pioneer Secretary General/Trustee-Director of the Charity, NMF (Nigerian Medical Forum UK) which took the BMJ to West Africa in 1995. Joseph is a member of the HIFA Steering Group; the HIFA working group on Community Health Workers, and the Working Group on HIFA-WHO Collaboration ( Email: info AT and jneana AT